Navigation Links
CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2013
Date:8/21/2013

ATLANTA, Aug. 21, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the third quarter 2013 of $0.0275 per share of common stock outstanding.  The quarterly cash dividend of $0.0275 per share will be paid on September 20, 2013 to all common stockholders of record as of September 13, 2013.  The ex-dividend date for the quarterly dividend is September 11, 2013. 

CryoLife anticipates paying quarterly dividends in March, June, September, and December of each year.  Based on the number of shares currently outstanding, the Company currently expects to pay a total annual dividend of approximately $3.0 million.  These statements represent management's current beliefs and expectations and are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. As such, they are subject to risks and uncertainties that could cause future events to deviate from current expectations, including without limitation that the declaration of future dividends and the establishment of the per share amount, record dates, and payment dates for future dividends are subject to final determination by the Company's Board of Directors, and will be dependent upon future earnings, cash flows, financial and lender requirements, the Board's evaluation of competing uses for available cash, and other factors.

About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S., certain countries in Europa, and Canada.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.  CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  Additional marketing approvals for BioGlue have been granted in several other countries throughout the world.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  In addition, CryoLife and its subsidiary Hemosphere, Inc. market the HeRO® Graft, which is a solution for end-stage renal disease in certain hemodialysis patients.  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community and other select international countries.  CryoLife's BioFoam™ Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. 

For additional information about CryoLife, visit CryoLife's website, www.cryolife.com.

Contacts:

CryoLife

D. Ashley Lee

Executive Vice President, Chief Financial Officer

and Chief Operating Officer

Phone: 770-419-3355

The Ruth Group

Nick Laudico / Zack Kubow

646-536-7030 / 7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com

 


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife kündigt erste Implantation des HeRO Transplantats in Europa an
2. CryoLife anuncia el primer implante europeo del injerto HeRO
3. CryoLife annuncia il primo impianto europeo di HeRO Graft
4. CryoLife Announces First European Implant Of HeRO Graft
5. CryoLife Reports Record Second Quarter Revenues
6. CryoLife Announces Release Date and Teleconference Call Details for 2013 Second Quarter Financial Results
7. CryoLife Enhances International Presence with Appointment of Andres Sarmiento as Latin America Sales Manager
8. CryoLife 2013 First Quarter Revenues Grew 10 Percent to a Record $35.5 Million
9. CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial Results
10. CryoLife Receives FDA Clearance For Next Generation HeRO Device
11. CryoLife Expands Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017   Protein Sciences Corporation , a leading ... Vaccine , announced today that they donated 45,000 doses ... (PIVI) and the Mongolian Ministry of Health to help ... The doses of Flublok have been distributed and used ... for health care workers, pregnant women, and those from ...
(Date:2/22/2017)... , February 22, 2017 According ... "Radiology Information System Market by Type, Component, Deployment Mode and ... radiology information system market was valued at $603 million in ... growing at a CAGR of 5.9% from 2016 to 2022. ... of the total market in 2015. ...
(Date:2/22/2017)... Feb. 22, 2017  Based on its recent ... & Sullivan recognizes SnooZeal, Inc. with the 2017 ... highly innovative product that intelligently addresses the root ... muscles through the clinically proven continuous transmucosal electrical ... SnooZeal is one of the most accessible anti-snoring ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® is providing a ... have recently fallen victim to America’s opioid epidemic. Now, opiate dependent individuals can be ... are free from the shame, stigma, and harmful labeling believed to prevent ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients with ... the emergency room, fewer hospital admissions, and better blood pressure and glycemic control, ... finds. The study can be found here . , The study comes ...
(Date:2/22/2017)... Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... the recent addition of esteemed ophthalmologist, Dr. Steven H. Rauchman, practicing at North ... common in auto accidents, product liability, premise liability and other personal injury cases. ...
(Date:2/22/2017)... ... 22, 2017 , ... The first-ever National Heart Valve Disease ... individuals join together to increase recognition about the risks of heart valve disease ... we mark a nationwide movement to raise awareness about a disease that has ...
(Date:2/22/2017)... ... 2017 , ... Bellus Medical, a leader in medical aesthetics, ... of Platelet Rich Plasma (PRP). PRP systems are used by physicians in areas ... and provide a faster and more efficient healing process. There are many systems ...
Breaking Medicine News(10 mins):